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Malignant peripheral nerve sheath tumors (MPNST) are aggressive cancers that occur spontaneously 
(sporadic MPNST) or from benign plexiform neurofibromas in neurofibromatosis type 1 (NF1) patients. 
MPNSTs metastasize easily, are therapy resistant and are frequently fatal. The molecular changes 
underlying the malignant transformation in the NF1 setting are incompletely understood. Here 
we investigate the involvement of microRNAs in this process. MicroRNA expression profiles were 
determined from a series of archival, paired samples of plexiform neurofibroma and MPNST. Ninety 
differentially expressed microRNAs were identified between the paired samples. Three downregulated 
microRNAs (let-7b-5p, miR-143-3p, miR-145-5p) and two upregulated microRNAs (miR135b-5p and 
miR-889-3p) in MPNST were selected for functional characterization. In general, their differential 
expression was validated in a relevant cell line panel but only partly in a series of unpaired, fresh frozen 
tumor samples. As part of the validation process we also analyzed microRNA expression profiles of 
sporadic MPNSTs observing that microRNA expression discriminates NF1-associated and sporadic 
MPNSTs. The role of microRNAs in cancer progression was examined in NF1-derived MPNST cell lines by 
transiently modulating microRNA levels. Our findings indicate that some microRNAs affect migratory 
and invasive capabilities and Wnt signaling activity but the effects are distinct in different cell lines. We 
conclude that miRNAs play essential regulatory roles in MPNST facilitating tumor progression.
Neurofibromatosis type 1 (NF1) is a relatively common autosomal dominant disorder which is caused by inher-
ited or sporadic mutations in the NF1 gene1–3. The NF1 gene encodes the tumor suppressor neurofibromin 1 that 
functions as a negative regulator of Ras signaling by its GTPase- activating protein (GAP) domain. The partial 
inactivation of neurofibromin 1 seen in NF1 patients can cause variable symptoms affecting the skin, bone and 
the nervous system. Moreover, the disease is associated with an increased risk of benign and malignant tumor 
formation. Almost all NF1 patients develop cutaneous neurofibromas and in many instances also deeper seated 
plexiform neurofibromas. These benign tumors are believed to originate from the Schwann cell lineage i.e. mature 
Schwann cells or Schwann cell precursors4,5 and are characterized by a biallelic inactivation of the NF1 gene1,6. 
Approximately 10% of NF1 patients develop malignant peripheral nerve sheath tumors (MPNSTs) usually in the 
context of pre-existing plexiform neurofibromas. MPNST are highly aggressive tumors that are largely respon-
sible for the reduced life expectancy these patients face7–9. Early metastasis, poor prognosis, and resistance to 
therapeutic interventions are common clinical features of this cancer. While patients with non-metastatic disease 
may benefit from surgical resection and radiation, many patients relapse. These patients, and also those initially 
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presenting with advanced disease, face a poor prognosis as there are only a limited number of systemic agents 
available for these patients such as doxorubicin, ifosfamide and pazopanib. The relatively modest anti-tumor 
activity of these agents translates in a median overall survival of approximately one year10,11. A better understand-
ing of the essential molecular mechanisms underlying plexiform neurofibroma transformation to MPNST is 
crucial to reveal NF1 patients who are at risk to develop MPNST and to identify new targets for treatment.
MicroRNAs (miRNAs) are a class of small non-protein coding RNAs of approximately 19–26 nucleotides in 
length that function in post-transcriptional gene regulation. They generally operate by binding, in the context 
of the RNA induced silencing complex (RISC), to the 3′ untranslated region of target mRNAs. MiRNA binding, 
through base pairing between the miRNA and mRNA, cause mRNA degradation and/or inhibition of trans-
lation12,13. Over the past two decades it became clear that miRNAs fulfil pivotal roles in a wide variety of bio-
chemical and physiological processes and are intimately involved in numerous pathological processes including 
cancer14–17. A dysregulated miRNA expression profile is a key characteristic of cancer and can be exploited for 
diagnostic purposes. There is ample evidence that miRNAs can have oncogenic or tumor suppressive proper-
ties. However, in many instances the extent to which individual – aberrantly expressed – miRNAs contribute 
to carcinogenesis and cancer progression and/or affect treatment response is not fully understood. A limited 
number of miRNA profiling studies examined human neurofibroma and NF1-derived MPNST tumor samples 
and implicated the involvement of several miRNAs in the malignant transformation of plexiform neurofibroma 
to MPNST18–21. Although of interest, these studies are difficult to compare as different miRNA detection plat-
forms were used, variable numbers of unpaired tumor samples were examined and only a few miRNAs were 
functionally characterized. Here we analyzed miRNA expression, using an established and highly reproducible 
RT-PCR procedure, in a unique series of paired human archival tumor samples of plexiform neurofibroma and 
MPNST. Each individual neurofibroma/MPNST pair being derived from the same NF1 patient. The expression of 
a selected set of differentially expressed miRNAs was validated using a well-characterized neurofibroma/MPNST 
cell line panel as well as fresh frozen samples of plexiform neurofibromas, atypical neurofibromas and MPNST. 
To understand how these miRNAs affect carcinogenesis and/or MPNST progression we modulated their expres-
sion levels in MPNST cell lines and assessed their impact on cellular proliferation, migration and invasion and 
Wnt/β-catenin signaling.
Materials and Methods
Tumor samples. Neurofibromatosis type 1 patients from which both archival plexiform neurofibroma as 
well as MPNST resection samples were available were identified in the Erasmus Medical Center patient files. 
Formalin-fixed paraffin-embedded (FFPE) tissue blocks were collected, from the Erasmus MC Tissue bank, of 
a set of nine neurofibroma-MPNST pairs (see Supplementary Table 1 for patient and tumor characteristics). In 
addition, ten FFPE tumor tissue blocks were collected that were derived from patients diagnosed with sporadic 
MPNST (Supplementary Table 2). Fresh frozen tumor samples from plexiform neurofibroma (n = 7), atypical 
neurofibroma (n = 4) and NF1-associated MPNST (n = 11) (Supplementary Table 3) from the Erasmus MC tissue 
bank were included for validation purposes. Hematoxylin-eosin-stained sections of these samples were examined 
by an expert pathologist at the Erasmus MC (RMV) to confirm the initial histopathological diagnosis using cri-
teria as described before22,23 in accordance with the 2016 WHO classification of Tumours of the Central Nervous 
System24. The experimental protocol was submitted for review to, and approved by, the Medical Ethics Committee 
Erasmus MC of Rotterdam (MEC-2016-213). All experimental procedures, including the use of human tissues 
samples, were performed in accordance with the relevant guidelines and regulations, with all researchers adhering 
to the code of conduct for medical research as laid out by the council of the Federation of Dutch Medical Scientific 
Societies (https://www.federa.org/codes-conduct). The use of anonymous or coded left-over material for scien-
tific purposes is part of the standard treatment agreement with patients and therefore informed consent was not 
required according to Dutch law.
Cell culture. The human NF1-associated MPNST derived cell lines 90-8TL, ST88-14 and the sporadic 
MPNST derived STS26T cell line were a kind gift of Dr. Eduard Serra (Institute of Predictive and Personalized 
Medicine of Cancer/IMPPC, Barcelona, Spain). The sNF96.2 cell line (NF1-derived MPNST) and the HS53T 
cell line (cutaneous neurofibroma) were obtained from the American Type Culture Collection (ATCC). All cell 
lines were routinely cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco Life Technologies) sup-
plemented with 10% fetal bovine serum (FBS), 100 IU/ml penicillin and 100 µg/ml streptomycin at 37 °C in a 
humidified atmosphere containing 5% CO2. All cell cultures were regularly screened for mycoplasma infection. 
Short Tandem Repeat (STR) profiles of the cell lines were established for authentication purposes (Supplementary 
Fig. 1) and were matched to source profiles at the ATCC, Deutsche Sammlung von Mikroorganismen und 
Zellkulturen (DSMZ) or the literature when available.
RNA isolation. Total RNA was extracted from 5–6 20 µm sections from each FFPE tumor sample using the 
RecoverAllTM total nucleic acid isolation kit (Ambion/Life Technologies) according to the manufacturer’s recom-
mendations. RNAbee (Tel test Inc.) was used to isolate total RNA from cell pellets and fresh frozen tumor tissue 
samples following standard protocols. The quality and concentration of all the RNA preparations were examined 
using a Nanodrop-1000 (Nanodrop Technologies).
MicroRNA profiling. The miRNA expression profiles were determined in FFPE samples using TaqMan® 
Low Density Array (TLDA) Human MicroRNA Cards (A card v2.0, B card v3.0; Applied Biosystems/Thermo 
Fisher Scientific) capable of detecting 756 distinct human miRNAs essentially as previously described25. 
In brief: Two pools of cDNA were prepared using Megaplex™ RT Primers Human Pools (pool A v2.1, pool 
B v3.0) and a Taqman® microRNA reverse Transcription kit (Applied Biosystems/Thermo Fisher Scientific). 
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Next, a pre-amplification step was carried out using Megaplex™ PreAmp Primers Human Pools (pool Av2.1, 
pool B v3.0) together with the Taqman™ PreAmp master-mix (Applied Biosystems/Thermo Fisher Scientific). 
The resulting products were further amplified using Taqman™ Universal PCR Master-Mix No AmpErase® on 
human microRNA A and B cards in a 7900HT Fast Real-Time PCR system (Applied Biosystems/Thermo Fisher 
Scientific). The expression (CT value) of a specific miRNA in a sample was normalized to the median CT of all 
detectable miRNAs in that sample. Subsequently the normalized relative expression (2−ΔCT) was calculated for 
each miRNA. The normalized miRNA expression data were log 2 transformed and median centered to acquire the 
relative expression values that were used for hierarchical clustering analyses using Cluster-3.0 and Java TreeView 
for visualization. The clustering was based on the uncentered correlation as a distance metric using average link-
age. A Student T-test (paired) was used to determine statistical significance between distinct groups of expression 
data and the Benjamini-Hochberg false discovery rate (FDR) was used to control for multiple testing.
RT-PCR. The expression level of individual miRNAs was determined using the TaqMan® MiRNA Assays 
Technology (Applied Biosystems/Thermo Fisher Scientific) in a neurofibroma/MPNST cell line panel and 
fresh frozen tumor samples. In brief: Total RNA (50 ng) was reverse transcribed in a multiplex reaction using 
specific miRNA primers from the TaqMan® MiRNA Assays and reagents from the TaqMan® MiRNA Reverse 
Transcription Kit (Applied Biosystems/Thermo Fisher Scientific) according to the manufacturer’s protocol. The 
resulting cDNA was used as input in a quantitative real-time PCR (qPCR) using a miRNA specific primer/probe 
mix together with the TaqMan® Universal PCR Master Mix No AmpErase® UNG (Applied Biosystems/Thermo 
Fisher Scientific) using the 7500 Fast Real-Time PCR systems (Applied Biosystems/Thermo Fisher Scientific). 
The qPCR data were analyzed using SDS software (version 2.4, Applied Biosystems/Thermo Fisher Scientific). A 
standard dilution series of a cDNA sample-pool was included on every plate allowing for the absolute quantifica-
tion of the miRNA expression.
The mRNA expression of Wnt target genes was determined by RT-PCR using the TaqMan® Technology 
(Applied Biosystems/Thermo Fisher Scientific). In brief: Total RNA (1 µg) was used as input for a reverse tran-
scription reaction using a high capacity cDNA reverse transcription kit (Applied Biosystems/Thermo Fisher 
Scientific) according to protocols of the manufacturer. The cDNA was used as input in a PCR reaction using 
primer/probe combinations from the following Taqman® gene expression assays (LEF1, assay ID: Hs01547250_
m1; MSX2, assay ID: Hs00741177_m1; SOX9, assay ID:Hs00165814_m1; TWIST1, assay ID: Hs00361186_m1) 
and Taqman® Universal PCR master mix using the 7500 Fast Real-Time PCR system (all obtained from Applied 
Biosystems/Thermo Fisher Scientific) according to the manufacturer’s recommendations. Three housekeepers 
(GAPDH, HPRT and PPIA) were used for normalization purposes using the comparative CT-method26. The 
qPCR data were analyzed using SDS software (version 2.4, Applied Biosystems/Thermo Fisher Scientific).
Transfections. Human MPNST cells were plated in 96-well plates at a concentration of 2–18 × 103 cells/well 
(SNF96.2); 2–10 × 103 cells/well (ST88–14) and 2–10 × 103 cells/well (90-8TL) in a total volume of 200 μl of stand-
ard cell culture medium without antibiotics. After 24 h cells were transfected with 50 nM MiRIDIAN microRNA 
mimics (Dharmacon) of let7b-5p, miR-143-3p, miR-145-5p and miR-29c-3p or 50 nM MiRCURY LNATM inhib-
itors (Exiqon) of miR-135b-5p and miR-889-3p. As controls a scrambled miRNA mimic Negative control #1 
(Dharmacon) and the miRCURY LNATM inhibitor Negative Control (Exiqon) were used. DharmaFECT I was 
used as a transfection reagent. Transfection conditions were optimized (transfection efficiency > 90%) for each 
of the cell lines using a fluorescently labelled miRNA mimic (miRIDIAN mimic transfection control Dy547; 
Dharmacon) (Supplementary Fig. 2).
Proliferation assay. Twenty-four hours prior to transfection, cells were plated in a 96-well plate. The next 
day the cells were transfected at approximately 40–50% confluency with selected miRNA mimics/inhibitors or 
appropriate controls. Cell viability was assessed by a sulforhodamine B (SRB) assay at 72 h post-transfection 
essentially as described previously27. In short: cells were fixed by 10% TCA in PBS, washed and stained by 0.4% 
SRB in 1% acetic acid for 15 min, washed in 1% acetic acid and dried. Color was dissolved in Tris-Base after which 
the A540nm was measured using a spectrophotometer.
Migration assays. Wound healing kinetics. Twenty-four hours prior to transfection, cells were plated in a 
96-well ImageLockTM plate (Essen BioScience Ltd.). The next day the cells were transfected with selected miRNA 
mimics/inhibitors or appropriate controls. At 24 h post-transfection, all 96 wells were scratched simultaneously 
in the central axis of the individual wells using the WoundMakerTM (Essen Bioscience Ltd.). A live-cell imaging 
system, IncuCyte (Essen BioScience Ltd.) was used to automatically monitor the kinetics of cell migration every 
2 hours for a total duration of 26 h during which cells migrate from the scratch edges into the wound area.
Cell-speed measurements. Twenty-four hours prior to transfection, cells were plated in a 96-well 
CellCarrierTM-96 Ultra microplate (PerkinElmer). The next day the cells were transfected with selected miRNA 
mimics or appropriate controls. At 24 h post-transfection cells were imaged at 2 h intervals in an Opera Phenix™ 
HCS system (PerkinElmer) for 40 h. Software (Harmony® High Content Imaging and Analysis Software, 
PerkinElmer) was used to calculate the average cell speed of the individual cells in the wells of the microplate.
Invasion assay. Cells were cultured in a 6-well plate and transfected with selected miRNA mimics/inhib-
itors or appropriate controls. At 24 h post-transfection the cells were harvested by mild trypsinization, resus-
pended in DMEM supplemented with 2.5% FBS and plated into the IncuCyteTM ClearView 96-well insert (Essen 
BioScience Ltd.) at a concentration of 2 × 103 cells/well (SNF96.2); 2 × 103 cells/well (ST88–14) and 7.5 × 103 
cells/well (90-8TL). Prior to plating the transfected cells, the IncuCyte ClearView insert membranes were coated 
with 50 μg/ml Matrigel (BD Biosciences). The inserts were subsequently placed in a 96-well plate containing 
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DMEM supplemented with 10% FBS and incubated under standard cell culture conditions. An IncuCyte live-cell 
imaging system (Essen BioScience Ltd.) was used to capture cell invasion monitoring and quantifying invading 
cells through the matrigel coated membranes every two hours for a total period of 67 h.
Wnt reporter assay. Wnt/β-catenin signaling activity was determined by a β-catenin/TCF reporter assay 
in a two-step transfection process. In brief: SNF96.2, ST88-14 and 90-8TL cell lines were plated in 24-well plates 
in culture medium without antibiotics. When the cells reached 60–70% confluency they were transfected with 
MiRCURY LNATM inhibitors (Exiqon) of miR-135b-5p, miR-889-3p or a miRCURY LNATM inhibitor Negative 
Control (Exiqon) in a final concentration of 50 nM using Dharmafect I. After 24 h the cells were co-transfected 
with 250 ng of the TOP-Flash or FOP-Flash firefly luciferase reporter constructs28 and 25 ng of a SV40-Renilla 
luciferase expression (for normalization purposes) using FuGene ®HD (Promega). Eight hours post-transfection 
the cells were stimulated with 25% L-control medium in DMEM or 25% L-Wnt3A medium in DMEM and left to 
incubate for 16 h after which the cells were lysed and assayed for firefly and Renilla luciferase activities using the 
Dual-Luciferase reporter assay system (Promega).
Results
Plexiform neurofibromas can be distinguished from MPNST by their microRNA expression 
profile. To study the involvement of miRNAs in the malignant transition of benign plexiform neurofibro-
mas into MPNST we determined the miRNA expression profiles of a unique series of nine paired plexiform 
neurofibromas and MPNST samples. Each plexiform neurofibroma/MPNST pair was derived from the same 
NF1 patient. An unsupervised hierarchical clustering, based on the expression of all detectable miRNAs in these 
paired samples, already grouped most of the benign plexiform neurofibromas and MPNSTs in distinct clusters 
(Supplementary Fig. 3). A supervised clustering analysis using the 90 most significant differentially expressed 
miRNAs (p < 0.025; FDR < 10%) between neurofibromas and MPNSTs grouped the samples into clearly separate 
clusters (Fig. 1, Supplementary Table 4). The majority (82 out of 90; 91%) of the differentially expressed miRNAs 
were found to be downregulated in the MPNST group in comparison to the plexiform neurofibromas. The down-
regulated miRNAs include members of well-known cancer related miRNA clusters like the miR-23/27/24 clusters 
on chromosome 9-q22.32 and 19-p13.12, the miR-143/145 cluster on 5-q33.1, the miR-29b-1/29a and miR-29b-
2/29c clusters on chromosome 7-q32.3 and 1-q32.2, respectively. In addition, 5 members of the let-7 family, let-
7a/b/c/d/e were found downregulated in MPNST. Only 8 (9%) of the miRNAs exhibited a higher expression in 
the MPNST samples than in neurofibromas, these include miR-135b, miR-889, miR-493, miR-433 and miR-541, 
the last four all belonging to a large miRNA cluster on the long arm of chromosome 14 (14-q32.31). Particularly, 
miR-135b and miR-541 are aberrantly expressed in the MPNST setting with a 52-fold and 20-fold upregulation, 
respectively.
Validation of differentially expressed microRNAs between plexiform neurofibromas and 
MPNST in a cell line panel and fresh frozen tumor samples. It was investigated whether the dif-
ferential expression of a selected set of miRNAs could be validated in a well-characterized cell line panel and 
additional, unpaired fresh frozen neurofibroma and MPNST samples. Taking statistical significance (p < 5 × 10−4; 
FDR < 1%), fold-difference (>3 in at least 75% of the sample pairs) into account as well as the reported involve-
ment of miRNAs in cancer, we selected the following miRNAs for further validation and subsequent functional 
studies miR-145-5p, miR-143-3p, miR-139-5p and let-7b-5p all downregulated in MPNST and miR-135b-5p and 
miR-889-3p as representatives of the upregulated miRNAs (Fig. 1, Supplementary Tables 4 and 5). When con-
sidering the expression of the selected miRNAs in the individual NF-MPNST samples pairs it was noted that the 
fold-difference of the up or down-regulation varies considerably between different pairs (Supplementary Table 5). 
Using quantitative PCR, we could validate the expression of the selected miRNAs as shown in Fig. 2A. MiR-145, 
let-7b, miR-143 - and to a lesser extent miR-139-5p - were all downregulated in the MPNST cell lines STS26T, 
sNF96.2, ST88-14 and 90-8TL compared to their expression level in a cutaneous neurofibroma cell line Hs53.T. 
Conversely, miR-135b was found upregulated in MPNST cell lines. MiR-889 was clearly upregulated in ST-88-14 
and 90-8TL but downregulated in sNF96.2 and the sporadic MPNST cell line STS26T. In general, these results 
(Fig. 2C) confirm our miRNA profiling findings and identify the MPNST cell lines as representative models for 
this malignancy. As the expression distribution between neurofibroma and MPNST for miR-139-5p reflected our 
profiling results the least, we omitted this miRNA from further analyses. As additional validation we determined 
the expression levels of the selected miRNAs in fresh frozen samples from a plexiform neurofibroma/MPNST 
sample pair derived from the same patient (Fig. 2B). In agreement with our previous observations we demon-
strated downregulation of miR-145, miR-143 and let-7b whereas miR-135b and miR-889 were upregulated in the 
MPNST sample. We also determined the expression levels of the selected miRNAs in a larger unpaired panel of 
fresh frozen tumor samples consisting of plexiform neurofibromas (n = 6), atypical neurofibromas (n = 4) and 
MPNSTs (n = 10) (Fig. 3). The expression level of the miRNAs in atypical neurofibroma samples is not signifi-
cantly different from the expression observed in plexiform neurofibromas. A comparison between the miRNA 
expression levels in MPNST and neurofibromas indicated a significant downregulation in the MPNST group 
of let-7b (p < 0.01) and of miR-145 when the expression levels in MPNST were compared to levels in atypical 
neurofibromas (p < 0.05). A comparison of miR-145 levels between MPNST and plexiform neurofibromas was 
borderline significant (p = 0.0572). Likewise, the expression of miR-143 between MPNST and atypical neurofi-
bromas was borderline significant (p = 0.0584). No significant statistical difference between sample groups was 
observed for miR-889, miR-143 and miR-135b expression. The high variability observed in the expression levels 
of the selected miRNAs, particularly in the MPNST samples, most likely reflects tumor heterogeneity and may 
obscure differences. This problem may be partly overcome by analyzing paired samples.
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Figure 1. Differentially expressed microRNAs between plexiform neurofibromas and MPNST. The miRNA 
expression profiles were determined of FFPE sections from nine paired sets of plexiform neurofibroma (NF) 
and MPNST tumor samples, each pair derived from the same NF1 patient that initially presented with a 
plexiform neurofibroma and at a later stage developed an MPNST. Depicted are the results of a supervised 
hierarchical clustering using the most differentially expressed miRNAs (p < 0.025, FDR < 10%) in the analyses. 
The color code on top indicates the relative position of the neurofibroma-MPNST pairs in the cluster tree. The 
heat map lists the individual miRNAs and their relative expression levels in the MPNST and neurofibroma 
clusters. Red arrows indicate miRNAs that were selected for further validation and functional studies. In 
the heat map red indicates relative high expression, green relative low expression, grey designates missing 
expression values.
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NF1-associated MPNST and sporadic MPNST display distinct miRNA expression profiles. To 
assess whether the selected miRNAs are specifically dysregulated in NF1-derived MPNST, we examined miRNA 
expression in 10 archival sporadic MPNST samples. A comparison between the miRNA profiles observed in 
the sporadic MPNST and the NF1-derived MPNST revealed many differentially expressed miRNAs (Fig. 4, 
Supplementary Table 6, Supplementary Fig. 4) emphasizing these tumor types have a different etiology and possi-
bly a different biology. A cluster analysis using the 45 most significantly differentially expressed miRNAs (p < 0.03, 
FDR < 10%) completely discriminated the two MPNST types (Fig. 4). Very few of the miRNAs identified in the 
plexiform neurofibroma-MPNST comparison, and none of the selected miRNAs, were detected in the sporadic 
MPNST – NF1-derived MPNST comparison. Apparently, the selected miRNAs were not differentially expressed 
between sporadic and NF1-derived MPNST. Therefore, we cannot rule out that the selected miRNAs are also 
aberrantly expressed in sporadic MPNST and play a role in carcinogenic processes in these tumors as well.
MicroRNAs affect migratory and invasive capacity of MPNST cell lines. The selected miRNAs 
that are dysregulated in NF1-associated MPNST may contribute to the process of tumorigenesis and metastasis. 
All have been linked to various aspects of carcinogenesis in other cancers. The clustered miR-143 and miR-145 
genes are widely regarded as tumor suppressors in epithelial tumors29–32 and were indicated as having a critical 
role in tumor stroma33,34. MiR-135b has been implicated in the progression of several cancers35–37 and let-7b is 
considered a tumor suppressor miRNA38. In vitro experiments were conducted to examine the functional role of 
the selected miRNAs and their effect on cellular proliferation, migration and invasion. To that end, transiently, the 
expression levels of let-7b, miR-145 and miR-143 were restored and miR-135b and miR-889 levels were reduced, 
in MPNST cell lines. As a control we included a miR-29c mimic. This miRNA was reported by Presneau et al. to 
be reduced in MPNST and to affect migration and invasion, but not proliferation20.
Figure 2. Expression of selected microRNAs in a neurofibroma/MPNST cell line panel and in a fresh frozen 
neurofibroma/MPNST sample pair. (A) Expression levels measured by quantitative RT-PCR of selected 
miRNAs (miR-145-5p, let-7b-5p, miR-143-3p, miR-135b-5p, miR-889-3p and miR-139-5p) in a well-
characterized cell line panel consisting of a cutaneous neurofibroma cell line (HS53T), NF1-associated MPNST 
cell lines (SNF96.2, ST88-14, and 90-8TL) and a sporadic MPNST cell line (STS26T). Bars depict average 
values ± SD (n = 3–4). A T-test was used to determine statistical significance; *p-value < 0.05, **p-value < 0.01. 
(B) Expression level of selected miRNA in a fresh frozen plexiform neurofibroma/MPNST sample pair derived 
from the same NF1 patient. (C) Summary of the expression level fold-changes of selected miRNAs in the 
MPNST cell lines compared to the expression level observed in the cutaneous neurofibroma cell line HS53.T.
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First, we focused on cellular proliferation using an SRB assay to assess the effects of miRNA modulation. By 
quantifying the amount of cells in time, comparing control transfections with miRNA mimic/inhibitor trans-
fections we determined whether cell proliferation was affected. It was observed that none of the miRNA mimics 
or inhibitors significantly and consistently affected proliferation with the exception of miR-29c overexpression 
in sNF96.2 which stimulated cell proliferation (Supplementary Fig. 5). We next assessed whether the selected 
miRNAs affect the migratory and invasive capacity of the tumor cells. We performed a scratch assay to measure 
the migration potential of the transfected MPNST cells. Figure 5 depicts representative results on the kinetics 
of migration in sNF96.2 and ST88-14 transfectants obtained by a live-cell imaging system. Most miRNA mim-
ics and inhibitors did not significantly interfere with the migratory capacity of the MPNST cells (Fig. 5A,C). 
However, a clear reduction of the migration rate was observed in sNF96.2 cells transfected with let-7b (Fig. 5B) 
and in ST88-14 cells transfected with miR-29c (Fig. 5D). None of the miRNA mimics and inhibitors had an effect 
on the migration capacity of 90-8TL cells (Supplementary Fig. 6A). These observations were confirmed when 
Figure 3. Expression level of selected microRNAs in unpaired fresh frozen plexiform neurofibroma, atypical 
neurofibroma and MPNST samples. A quantitative RT-PCR was used to determine miRNA levels of miR-
145-5p, let-7b-5p, miR-143-3p, miR135b-5p and miR-889-3p in unpaired fresh frozen NF1-derived MPNST 
(n = 10), plexiform neurofibroma (NF; n = 6) and atypical neurofibroma (Atyp NF; n = 4). Relative expression is 
depicted using Box-Whisker plots with boxes showing 1st to 3rd quartile with the median marked by a horizontal 
line. A Mann Whitney U test was used to determine statistical significance; **p-value < 0.01, *p-value < 0.05.
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we determined the average cell speed as a measure for migratory capacity using a different cell imaging system 
(Supplementary Fig. 7).
Next, we examined the effect of the selected miRNAs on the invasive capacity of MPNST cells in a cell inva-
sion assay. The MPNST cell lines sNF96.2 and ST88-14 were transfected and seeded onto 96-well invasion plates 
containing a matrigel coated membrane. Invasion of cells was quantitatively monitored by live-cell imaging in 
Figure 4. Differentially expressed microRNAs between NF1-derived and sporadic MPNST. The miRNA 
expression profiles derived from FFPE sections of sporadic MPNST (sMPNST) (n = 10) are compared with the 
miRNA profiles from NF1-derived MPNST (n = 9, see Fig. 1). Depicted is a supervised hierarchical clustering 
using the most significant differentially expressed miRNAs (p < 0.011, FDR < 10%). The heat map lists the 
miRNAs and their relative expression levels. The differences indicate the different etiology of sporadic and NF1 
derived MPNST and may reflect a different biology. In the heat map red indicates relative high expression, green 
relative low expression, grey designates missing expression values.
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time. A strikingly reduced invasive capacity was observed in ST88-14 transfected with miR-135b (p < 0.01) and 
miR-889 (p < 0.03) inhibitors (Fig. 6C). These effects, however, were not seen in sNF96.2 transfectants (Fig. 6A) 
or 90-8TL transfectants (Supplementary Fig. 6B). In sNF96.2 cells, transfection with let-7b (p < 0.01) and miR-
29c (p < 0.01) mimics, and to a lesser extent with miR-145 (p < 0.05) resulted in reduced invasiveness (Fig. 6B). 
In contrast, miR-143 (p < 0.01) and miR-145(p < 0.01) mimics appeared to boost invasion in ST88-14 (Fig. 6D). 
We conclude that miRNA modulation effects are cell line dependent.
miR-135b and miR-889 modulate Wnt/β-catenin signaling in MPNST cells. Recently the canon-
ical Wnt/β-catenin signaling pathway has been identified as driver pathway of both benign neurofibromas and 
MPNST39,40. Moreover, miR-135b was reported to target multiple negative regulators of Wnt like Adenomatous 
Polyposis Coli (APC)36. Likewise, miR-889, another overexpressed miRNA in MPNST, was also predicted to 
target APC according to TargetScan version 7.1. We therefore examined whether miR-135b (on average 52x 
higher in MPNST) and miR-889 (on average 3x higher in MPNST) (Supplementary Tables 4 and 5) are capable 
of modulating Wnt signaling activity in the MPNST setting. sNF96.2, ST88-14 and 90-8TL were transfected with 
miR-135b or miR-889 inhibitors. Next, we determined Wnt/ß-catenin signaling activity using a TCF/ß-catenin 
reporter assay. It was noticed that Wnt/ß-catenin activity upon induction with Wnt ligand was highest in ST88-
14 (Fig. 7A) and 90-8TL (Supplementary Fig. 6C) with relatively low Wnt activity being measured in sNF96.2 
(Fig. 7A). Transient reduction of miR-135b and miR-889 expression significantly impaired the induction of 
Figure 5. Effects of selected microRNAs on cell migration of the MPNST cell lines sNF96.2 and ST88-14. 
The NF1-associated MPNST cell lines sNF96.2 and ST88-14 were transfected with scrambled (LNA control), 
miR-135b and miR-889 inhibitors or with a scrambled (mneg control), miR-143, miR-145, let-7b and miR-
29c mimics. (A,C) Scratch assay after which cell migration is monitored every two hours for 26 h using a 
live-cell imaging system (IncuCyte; Essen Bioscience Ltd.). (B,D) Micrographs illustrating the effects of let-7b 
and miR-29c mimics on cell migration in sNF96.2 and ST88-14, respectively. The individual panels show the 
situation directly after scratching (left panels), at 14 h (middle panels) and after 26 h (right panels). Depicted are 
representative images and graphs, in the graphs individual data points indicate average values ± SD (n = 3).
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Wnt/ß-catenin signaling activity in ST88-14 (Fig. 7A). No significant effects were observed in the 90-8TL despite 
the relatively high Wnt activity levels observed in this cell line (Supplementary Fig. 6C). A small but significant 
reduction of Wnt activation was seen in miR-889 inhibitor transfectants of sNF96.2 but not in the miR-135b 
inhibitor transfectant (Fig. 7A). To verify that Wnt signaling is indeed affected the mRNA expression levels of 
Wnt target genes LEF1, MSX2, SOX9 and TWIST1, all genes expressed in MPNST and Schwann cells39, were 
determined by quantitative PCR  (Fig. 7B). ST88-14 cells that display active Wnt signaling (Fig. 7A) were trans-
fected with control, miR-135b and miR-889 inhibitors. Figure 7B indicates that miR-135b inhibition consist-
ently showed a trend of lowering the expression level of the Wnt target genes compared to a control transfection 
although without reaching statistical significance. Inhibition of miR-889 gave rise to similar results but the reduc-
tion in expression of the Wnt targets seemed stronger, more persistant and reached statistical significance. We 
conclude that both the overexpressed miR-135b and miR-889 in NF1-associated MPNST may augment Wnt 
signaling activity.
Discussion
MPNSTs are highly aggressive tumors with a dismal prognosis for those confronted with advanced disease10,11. 
Half of these tumors arise in the context of NF1 from benign pre-existing plexiform neurofibromas7,41. Genetic 
aberrations associated with this transformation include mutations in CDKN2A42 and TP5343 and the recently dis-
overed loss-of-function mutations in SUZ12 and EED, essential components of the PRC2 complex44–46. However, 
the precise molecular mechanisms underlying this maligant transition are still unclear. We investigated the 
involvement of miRNAs in the tumorigenesis and progression of MPNST.
MiRNAs are intricately connected to cancer and play critical roles in cancer gene regulation and diverse 
aspects of tumorigenesis14–17. Until now only few studies addressed the miRNA involvement in neurofibroma and 
MPNST biology18–21. All studies reported clear differences in miRNA expression between plexiform neurofibro-
mas and MPNST when unpaired tumor samples were analyzed. However, the functional significance and patho-
logical roles of dysregulated miRNAs in the context of MPNST are not, or poorly studied. In 2010, Chai et al. were 
the first to point out the downregulation of let7a/b in MPNST cells and their effect on MPNST cell invasiveness18. 
We as well observed the downregulation of multiple let-7 family members, including let7a/b in MPNST and 
noticed that let-7b expression interfered with cellular migration and invasion in NF1-derived MPNST cell lines. 
Let-7 family members are known to target Ras47 it might therefore be that their relatively low levels in MPNST 
facilitate Ras signaling. Presneau et al. described a reduction of miR-29 members, most notably miR-29c, in 
MPNST20. They demonstrated that miR-29c played a role in tumor progression by controlling migration and 
invasion via the regulation of the matrix metalloproteinase-2 (MMP2)20. Our findings also indicated significantly 
lowered levels of miR-29a/b/c and we confirmed – although not in all NF1-derived MPNST cell lines – the effects 
Figure 6. Effects of selected microRNAs on the invasive capacity of the MPNST cell lines sNF96.2 and ST88-
14. (A–D) The NF1-associated MPNST cell lines sNF96.2 and ST88-14 were transfected with scrambled (LNA 
control), miR-135b and miR-889 inhibitors or with a scrambled (mneg control), miR-143, miR-145, let-7b and 
miR-29c mimics. Invasive capacity was monitored every two hours for 67 h using a live-cell imaging system 
(IncuCyte). Y-axis indicates the “Total phase object area normalized to the initial top value” as a measure for the 
invading cell population. Depicted are representative graphs individual data points indicate average values ± SD 
(n = 3). A Mann Whitney U test was used to determine statistical significance comparing the last 10 datapoints 
in each series.
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of miR-29c on migration and invasion48. Supplementary Table 7 presents an overview of all miRNAs that were 
found dysregulated in NF1-associated MPNST in comparison to plexiform neurofibromas in multiple studies. 
Note that in general only few miRNAs were found upregulated in MPNST and that most differentially expressed 
miRNAs display a reduced expression level in MPNST.
By comparing the miRNA expression profiles of a unique series of paired samples of neurofibromas and 
MPNST, we defined a group of miRNAs that are aberrantly expressed in NF1-derived MPNST. From the 90 miR-
NAs that were identified we chose six miRNAs to examine their functional role in the pathogenesis of MPNST. 
MiR-143/145, let7b, miR-139-5p, miR135b, and miR-889 were among the top 15 of differentially expressed miR-
NAs (Supplementary Table 4). All, with the exception of miR-889, were also reported as misexpressed in MPNST 
by other researchers (Supplementary Table 7). However, none of the miRNAs we examined, with the exception of 
Figure 7. Effects of miR-135b and miR-889 inhibition on Wnt signaling capacity and Wnt target expression in 
MPNST cell lines. The NF1-associated MPNST cell lines ST88-14 and sNF96.2 were transfected with scrambled 
(LNA control), miR-135b and miR-889 inhibitors. (A) Wnt/ß-catenin signaling activity upon induction by 
Wnt ligand was determined using a β-catenin/TCF reporter assay. Depicted are average values ± SD (n = 9) 
(B) mRNA expression levels of Wnt target genes (LEF1, MSX2, SOX9, TWIST1) in ST88-14 cell line. Transcript 
levels were measured by quantitative RT-PCR at 48 h and 72 h after transfection with scrambled (LNA control), 
miR-135b and miR-889 inhibitors. Depicted are normalised average expression values ± SD (n = 4-6). In both 
(A,B) a Mann Whitney U test was used to determine statistical significance, *p-value < 0.05, **p-value < 0.01.
1 2Scientific RepoRtS |         (2020) 10:2927  | https://doi.org/10.1038/s41598-020-59789-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
let-7b, has been studied in MPNST. We were able to validate the reduced expression of let-7b, miR-143/145 and 
the increased expression of miR-135b in MPNST using a relevant cell line panel. The upregulation of miR-889 
was only observed in two NF1 associated MPNST cell lines (ST88-14 and 90-8TL) and not in sNF96.2 and the 
sporadic MPNST cell line STS26T. The increased expression of miR-889 in MPNST, which is less striking than 
that of miR-135b, may be more variable and occur only in a subset of tumors. When we examined the expression 
of the selected miRNAs in an unrelated series of unpaired fresh frozen plexiform neurofibroma, atypical neurofi-
broma and NF1-derived MPNST samples the down or upregulation of most selected miRNAs could not be firmly 
established. This may be due to the limited number of samples, together with the highly variable expression of 
the miRNAs examined in the MPNSTs. These results, however, do emphasize the value of paired samples and the 
need to analyze well-characterized and adequately sized cohorts to account for tumor heterogeneity.
A direct comparison between sporadic MPNST and NF1-derived MPNST revealed that these two tumor types 
could be completely distinguished on the basis of their miRNA expression profiles. This result contrasts with the 
findings of Holtkamp et al. who reported that sporadic and NF1-derived MPNST could not be distinguished by 
their mRNA expression patterns49. However, this study only examined the expression of 558 genes comparing 6 
sporadic MPNSTs with 4 NF1-derived MPNST, due to its limited set-up differences may have been missed.
Functional experiments initially focused on proliferation, migration and invasion, all key elements of car-
cinogenesis and cancer progression. It was uncovered that the selected miRNAs did not affect proliferation but 
their overexpression (miR-143, miR-145 and let-7b) or inhibition (miR-135b, miR-889) interfered with migration 
and invasion although not all cell lines responded in a similar fashion and/or with equal intensity (Figs. 5 and 6; 
Supplementary Figs. 6 and 7). Recently Watson et al. implicated the Wnt/β-catenin signaling pathway to fulfil an 
essential role in both neurofibromas and MPNST showing that inhibition of Wnt signaling by small molecules 
reduced viability and induced apoptosis40. The precise biological basis of Wnt/β-catenin signaling activation is 
only partly known and involves the downregulation of members of the β-catenin destruction complex and the 
expression of R-spondin 2 potentiating Wnt signaling. When we measured Wnt/β-catenin signaling activity using 
a β-catenin/TCF reporter system we observed that cell lines do show a different Wnt-pathway activation upon 
exposure to Wnt ligand with high activity in ST88-14 and 90-8TL and low activity in sNF96.2. This difference 
may be caused by the variable expression levels of Wnt pathway genes in different cell lines as reported by Luscan 
et al.39. Transient inhibition of both miR-135b and miR-889 using antisense inhibitors reduced the capacity of 
ST88-14 to induce Wnt signaling upon stimulation. In agreement with this observation is the fact that miR-135b 
and miR-889 inhibitors impair invasion of ST88-14 cells as Wnt signaling has been shown to be involved in 
invasion in many cancer cells50. No clear effects were seen on proliferation and migration of this cell line upon 
miR-135b and miR-889 inhibition. It cannot be excluded that the inhibition of Wnt signaling by interfering with 
miR-135b and miR-889 levels is not potent enough to affect these processes.
An intriguing question is what causes the aberrant expression of miRNAs as seen in MPNST. It was recently 
reported that in about 60% of NF1-derived MPNST the PRC2 complex is inactivated44–46. The PRC2 complex is a 
well-known epigenetic modulator of gene expression51 by establishing di-and trimethylation of histon H3 lysine 
27 (HeK27me2 and HeK27me3) both critical epigenetic silencing marks. Inactivation of PRC2 leads to aber-
rant gene expression due to the loss of these silencing marks. A list of genes differentially expressed in MPNSTs 
with loss of PRC2 and those with wild-type PRC2 is presented by Lee et al.45. Interestingly the expression of 
LEMD1, the gene that harbors miR-135b in one of its introns, is also induced upon PRC2 inactivation. This 
may explain the clearly increased levels of miR-135b observed in at least some of the MPNST samples (Fig. 1, 
Supplementary Tables 4 and 5) as it is co-expressed with its host gene LEMD1. Of note, the increased miR-135b 
levels may enhance Wnt signaling activity in the MPNST cells. Likewise, PRC2 inactivation may affect the miRNA 
cluster on chromosome 14 that contains four of the miRNAs, including miR-889, that were found upregulated 
in MPNST. However, PRC2 inactivation does not readily explain the downregulation of miRNAs observed in 
MPNST. Interesting in this respect are findings of de Raedt et al. who demonstrated that inactivation of PRC2 
boosts the Ras signaling pathway which is already activated by the NF1 loss in these tumors44. Ras activation has 
been reported to downregulate the expression of miR143/145 cluster31 thereby explaining their relatively low 
levels in MPNST.
Our findings indicate that miRNAs operate in a cell line specific manner as different NF1-associated MPNST 
cell lines respond to miRNA modulation with different intensities or in a different fashion. It could be that the 
cell lines that comprise our MPNST cell line panel differ at a molecular level, perhaps reflecting different chro-
mosomal copy number alterations as commonly observed in MPNST samples52. This may cause the cell lines 
to respond differently to miRNA regulation. This is a highly relevant issue which is often overlooked, as usually 
only a limited number of cell lines is used in in vitro experiments to functionally characterize miRNAs. We have 
studied the cellular effects by modulating the levels of individual miRNAs transiently. It could very well be that 
miRNAs display additive, or even synergistic effects and give rise to more pronounced cellular phenotypes when 
their levels are modulated simultaneously.
conclusions
From our study we conclude that at least some miRNAs play essential regulatory roles in MPNST facilitating 
tumor progression. These, and other miRNAs that are aberrantly expressed in MPNST, may be exploited as bio-
marker, with miRNA presence and/or levels being measured in suspect plexiform neurofibroma biopsies or in 
the circulation where they may signal the presence of MPNST. These avenues should be explored and can be 
particularly valuable in the context of neurofibromatosis type 1, with patients having a 10–13% life time risk of 
developing MPNST. Finally, as miRNAs are powerful regulatory biomolecules their therapeutic potential should 
be investigated in the context of MPNST in addition to the exact biochemical pathways and genes they regulate. 
These investigations may identify novel drug targets and lead to more effective therapeutic strategies.
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